Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer

Summary

The purpose of this study is to explore the safety and feasibility of the Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for patients with locally advanced upper third gastric adenocarcinoma（cT2-4a, N-/+, M0）.

Conditions

• Stomach Neoplasms

Interventions

PROCEDURE

Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections

After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.

DRUG

oxaliplatin

oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.

Sponsors & Collaborators

• Peking University Cancer Hospital & Institute

  collaborator OTHER

• Southwest Hospital, China

  collaborator OTHER

• Fujian Provincial Hospital

  collaborator OTHER

• Zhangzhou Municipal Hospital of Fujian Province

  collaborator OTHER

• Shanghai Zhongshan Hospital

  collaborator OTHER

• Meizhou People's Hospital

  collaborator OTHER

• Guangdong Provincial People's Hospital

  collaborator OTHER

• Guangdong Provincial Hospital of Traditional Chinese Medicine

  collaborator OTHER

• Second Hospital of Jilin University

  collaborator OTHER

• The First Affiliated Hospital with Nanjing Medical University

  collaborator OTHER

• Nanfang Hospital, Southern Medical University

  collaborator OTHER

• Affiliated Hospital of Qinghai University

  collaborator OTHER

• The First Affiliated Hospital of Xiamen University

  collaborator OTHER

• RenJi Hospital

  collaborator OTHER

• West China Hospital

  collaborator OTHER

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• First Affiliated Hospital of Xinjiang Medical University

  collaborator OTHER

• The First Hospital of Putian City, Putian, Fujian

  collaborator OTHER_GOV

• Longyan City First Hospital

  collaborator OTHER

• Fujian Medical University

  lead OTHER

Principal Investigators

• Changming Huang, Professor · Fujian Medical University Union Hospital,China

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-09-01

Primary Completion

2017-10-12

Completion

2020-10-12

Countries

• China

Study Locations